Comparing brain stimulation techniques for impulsivity in borderline personality disorder
Reduction of Impulsivity in Patients With Borderline Personality Disorder Using Dual-site Transcranial Magnetic Stimulation
This study is testing a new brain stimulation technique to see if it can help people with borderline personality disorder reduce their impulsivity.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Hôpital le Vinatier Academic / other |
| Locations | 1 site (Bron, AURA) |
| Trial ID | NCT05942651 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to evaluate the effectiveness of a non-invasive brain stimulation technique called paired cortico-cortical associative stimulation (ccPAS) in reducing impulsivity among patients diagnosed with borderline personality disorder (BPD). Participants will be randomly assigned to receive either active ccPAS or a sham treatment, with the goal of enhancing connectivity between specific brain regions associated with impulsivity. The study will utilize a double-blind, parallel-group design to ensure unbiased results. By focusing on impulsivity, a key symptom of BPD, the trial seeks to provide insights into potential therapeutic interventions for this challenging condition.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with borderline personality disorder as confirmed by a structured psychiatric interview.
Not a fit: Patients with other chronic psychiatric conditions or those currently on specific medications that affect GABAergic transmission may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment options for patients with borderline personality disorder, specifically targeting impulsivity.
How similar studies have performed: Other studies utilizing non-invasive brain stimulation techniques have shown promise in treating various psychiatric disorders, suggesting potential for success in this novel application.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of BPD (established by a psychiatrist and confirmed in a structured interview using the MINI) based on the Diagnostic and Statistical Manual of Mental Disorders (DSM V). Exclusion Criteria: * Contraindications to TMS/MRI (pacemakers or other devices likely to interfere with the magnetic field). * Pregnant or breast-feeding women. * Ongoing anxiolytic treatment (benzodiazepines), neuroleptic treatment or anticonvulsants acting on GABAergic transmission ; 24 hours prior to the protocol. * Diagnosis of other chronic psychiatric pathology including bipolar disorder type I or II and addictions (except tobacco). * Protective measure (curatorship or guardianship)
Where this trial is running
Bron, AURA
- Centre Hospitalier Le Vinatier — Bron, Aura, France (Recruiting)
Study contacts
- Study coordinator: POULET Emmanuel, PUPH
- Email: emmanuel.poulet@chu-lyon.fr
- Phone: 0437915565
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.